Pharmacology, Biochemistry and Behavior 1993: Vol 46 Index

9 Pages·1993·1.9 MB·English

PHARMACOLOGY
BIOCHEMISTRY
AND
BEHAVIOR
VOLUME 46, 1993
SUBJECT AND AUTHOR INDEX
©
Pergamon Press
New York ¢ Oxford ¢ Seoul ¢ Tokyo
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR
US Editor-in-Chief
MATTHEW J. WAYNER
Division of Life Sciences, The University of Texas at San Antonio, San Antonio, TX 78249-0662
European Editor-in-Chief
SANDRA E. FILE
Psychopharmacology Research Unit, UMDS Division of Pharmacology, Guy’s Hospital
P.O. Box 3448, London SE! 9QH, UK
Editorial Advisory Board
L. AHTEE, Helsinki, Finland GEORGE F. KOOB, La Jolla, CA
L. ALLIKMETS, Tartu, Estonia CONAN KORNETSKY, Boston, MA
ROBERT L. BALSTER, Richmond, VA J. DAVID LEANDER, Indianapolis, IN
G. BIGGIO, Cagliari, Italy EMINY H. Y. LEE, Taipei, Taiwan
M. BRILEY, Castres, France ALLEN S. LEVINE, Minneapolis, MN
ALLAN C. COLLINS, Boulder, CO WILLIAM J. McBRIDE, Indianapolis, IN
DONALD V. COSCINA, Toronto, Ontario, Canada DONALD E. McMILLAN, Little Rock, AR
JACQUELINE N. CRAWLEY, Bethesda, MD JACK H. MENDELSON, Belmont, MA
A. DOMENEY, Bradford, UK ROBERT D. MYERS, Greenville, NC
ADRIAN J. DUNN, Shreveport, LA J. A. PRATT, Glasgow, UK
BURR EICHELMAN, Philadelphia, PA ROSARIO SAMANIN, Milan, Italy
WILLIAM J. FREED, Washington, DC HERMAN H. SAMSON, Winston-Salem, NC
RICHARD A. GLENNON, Richmond, VA PAUL R. SANBERG, Tampa, FL
F. G. GRAEFF, Sido Paulo, Brazil PHIL J. SKOLNICK, Bethesda, MD
M. R. C. GREENWOOD, Davis, CA S. C. STANFORD, London, UK
ROLAND R. GRIFFITHS, Baltimore, MD M.-H. THIEBOT, Paris, France
STEPHEN G. HOLTZMAN, Atlanta, GA DEREK VAN DER KOOY, Toronto, Ontario, Canada
AKIRA HORITA, Seattle, WA JEANNE M. WEHNER, Boulder, CO
CHRIS E. JOHANSON, Baltimore, MD BRUNO E. WILL, Strasbourg, France
HAROLD KALANT, Toronto, Ontario, Canada J.C. WINTER, Buffalo, NY
G. JEAN KANT, Washington, DC ALICE M. YOUNG, Detroit, MI
KATHLEEN M. KANTAK, Boston, MA IAN S. ZAGON, Hershey, PA
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR
US Editorial Office:
Matthew J. Wayner
Division of Life Sciences, The University of Texas at San Antonio, 6900 North Loop 1604 West
San Antonio, TX 78249-0662
Fax: [phone]
European Editorial Office:
Sandra E. File
Psychopharmacology Research Unit, UMDS Division of Pharmacology, Guy’s Hospital
P.O. Box 3448, London SE1 9QH, UK
Fax: [phone]
Production Editor:
Jonathan R. Goodnough
Pergamon Press, Tarrytown, NY 10591-5153
Publishing, Subscription, and Advertising Offices:
Pergamon Press Inc., 660 White Plains Road, Tarrytown, NY 10591-5153, USA, E-mail Address:
[email protected]; and Pergamon Press Ltd., Headington Hill Hall, Oxford OX3 OBW, UK
Published Monthly
Annual institutional subscription rate (1993): £785 (US$1256)
Sterling prices are definitive. US dollar prices are quoted for convenience only and are subject to exchange rate
fluctuation. Prices include postage and insurance and are subject to change without notice.
Pharmacology Biochemistry and Behavior, Vol. 46, pp . ITI-VIII, 1993 0091-3057/93 $6.00 + .00
Printed in the U.S.A. All rights reserved. Copyright © 1993 Pergamon Press Ltd.
SUBJECT INDEX
Acetylcholinesterase activity, 729 Apomorphine, 135, 283, 587, 769 CGS 10746B, 989
ACTH, 101 Appetite, 205 CGS 19755, 807
Activity, 243 Appetite suppression, 653 Chloramphenicol, 361
Adaptation, 445 Arterial blood pressure, 561 Chlordiazepoxide, 467
Addiction, 125 ATPase, 519 Chlorpromazine, 467
Adenylate cyclase, 289, 519 Attention, 415, 733 Chlorpyrifos, 219
Adrenal medulla, 225 Autoanalgesia, 661 Cholera toxin, 623
Adrenergic, 251 Autoradiography, 251, 631 Cholinergic factors, 911
Affective disorder, 243 Cholinesterase, 219
Aggression, 923 Bacterial lipopolysaccharide, 787 Cholinesterase in RBC and tissues, 827
Aging, 27, 101, 405, 415, 799 Behavior, 51, 759, 769, 787, 959, 967 Chronic ethanol treatment, 27
Agonist, 759 Behavioral activation, 581 Chronic treatment, 135
Agonistic behavior, 67, 873 Behavioral despair, 225 Cigarettes, 259
Agoraphobia, 715 Behavioral disorganization, 51 Circadian, 251
Agoraphobia (thigmotaxis), 973 Behavioral effects, 161 Circadian rhythm, 243, 609
AH 6809, 383 Behavioral facilitation, 397 Circadian rhythmicity, 45
Alcohol, 463, 985 Behavioral pharmacology, 435 Cl” influx, 723
Alcohol drinking, 365, 751 Behavioral responses, 781 Clomipramine, 215
Alcohol-nonpreferring rats, 173, 631, 723 Behavioral stimulation, 553 Clonazepam, 995
Alcohol-preferring rats, 173, 631, 723 Behavioural patterns, 709 Clonidine, 39, 111, 265, 623
Alcohol self-administration, 35 Benzodiazepine(s), 167, 331, 661 CNS, 631
Alcohol withdrawal, 365 Benzodiazepine receptors, 77, 161 Cocaine, 61, 125, 289, 703, 715, 835, 973,
Allotetrahydrodeoxycorticosterone, 8, adrenergic, 679 989
963 8-Adrenergic antagonists, 131 Coffee drinking, 527
a-Adrenoceptors, 39 8-Adrenergic receptors, 77 Cognition, 415, 799
a,-Adrenoceptor, i11 8-Funaltrexamine, 813 Cognitive deficits, 889
a-Ethyltryptamine (a-ET), 459 Binding, 295 Color and position discrimination, 733
a-Lipoic acid, 799 Blind humans, 45 Concurrent acute exercise, 827
a-Methyltryptamine (a-MeT), 459 Blinded rat pups, 609 Conditional interaction, 467
a@,-Receptor, 117 Blood alcohol, 365 Conditioned avoidance, 759, 769
Alprazolam, 89, 167 Blood glucose, 995 Conditioned avoidance responses, 673
Amiloride, 83 Blood pressure, 259 Conditioned taste aversion(s), 153, 593
AMPA receptors, 73, 703 Body temperature, 967 Conditioning, 149
AMPA/Kainate receptors, 881 Body weight, 209, 617 Conflict, 905
Amperozide, 125 Bradykinin, 751 Conflict test, 569
Amphetamine, 195, 459, 637, 653, 769, 819 Bradykinin antagonist, 751 Corticosterone, 101
Ampicillin, 361 Brain, 125, 205 CPP, 807
Amygdala, 275 BRL 35135, 953 Culture, 195
Analgesia, 145, 205 Bulimia nervosa, 679 (+ )Cyanopindolol, 349
Analogs, 295 Buspirone, 89, 569, 647, 905
Angiotensin converting enzyme inhibitor, D, receptor, 51
751 Ca?* channel antagonist, 365 D, receptor, 51
Angiotensin II, 751 Ca’* channels, 365 DA reuptake, 709
Animal model of depression, 215 Caffeine, 463, 733 DA turnover, 709
Ag nerve terminals, 973 Calcium, 553 [D-Ala”, NMePhe*,Gly-ol]Enkephalin, 587
Anorexia, 787 Calmodulin, 697, 847 DALDA, 391
Antagonism, 237 Cannabinoid, 575 DAMGO, 391
Antagonist, 759 Cannabis, 967 d-Amphetamine, 153
Antianalgesia, 331, 623 Carbohydrate suppression, 349 Death, 61
Antibiotics, 361 Carbon clearance test, 605 d-Fenfluramine, 101, 349
Anticonvulsant, 467 Carbon monoxide, 259 Defensive burying paradigm, 897
Antidepressants, 15, 423 Castration, 309 Defensive withdrawal paradigm, 897
Antiepileptogenic effect, 275 Catalepsy, 135, 303 Delayed matching-to-sample, 733
Antinociception, 295, 331 Catecholamine(s), 225, 251 Delta-9-tetrahydrocannabinol (A°-THC),
Anxiety, 569, 715, 897, 905, 967 Caudate-putamen, 251 295, 575
Anxiolytic, 467 CCK, 237 [D-Pen*,L-Pen*]Enkephalin, 587
Anxiolytic effect, 647 C57BL/6J mice, 35 (—)Deprenyl, 709
Ill
IV SUBJECT INDEX
Depression, 225, 243, 667 5-HT, receptor, 289 Hyperphagia, 679
Desipramine, 89 5-HT, receptor antagonists, 857 Hyperthermia, 383
Development, 83, 637 5-HT; antagonist, 535 Hyperthyroidism, 729
Diazepam, 61, 89, 435, 569, 905 5-HTergic drugs, 427 Hypertonic saline intake, 473
Diazepam capsule implants, 683 5-Hydroxytryptamine, 487 Hypothalamus, 697
Diazepam dependence in rats, 683 Fixed ratio (FR), 667 Hypothermia, 283, 309, 519, 729
Diazepam plasma levels, rats, 683 Flumazenil, 161, 683 Hypoxia, 867
Discriminative stimulus effects, 989 Flumazenil plasma levels, rats, 683
Diurnal, 283 Flunarizine, 867 ICI 118551, 953
Dizocilpine, 423 Fluoxetine, 933 ICS-205,930, 349
DOI, 349 Flupenthixol, 543 Idazoxan, 215, 265, 933
DOM, 459 Food and water intake, 787 Idebenone, 415
Dopamine agonist(s), 51, 269, 703, 769 Food consumption, 209 lloprost, 383
Dopamine antagonist, 769 Food intake, 205, 745, 933 Imipramine, 423
Dopamine receptor(s), 769, 863 Food reinforcement, 733 Immobility, 295, 647
Dopamine receptor antagonist, 453 Forced swim(ming) test, 111, 215, 225 Immune system, 787
Dopamine uptake sites, 863 Formalin, 661 Immunity, 445
Dopamine, 21, 51, 101, 183, 195, 303, 405, Foster mother, 609 Immunomodulator, 787
477, 543, 581, 715, 759, 769, 793, 867, Frontal cortex, 323 Incremental repeated acquisition, 733
881, 943, 973 Furosemide, 473 Indirect calorimetry, 617
Dorsal immobility response, 841 Indorenate, 569
Dorsal striatum (STr), 973 G,, 623 Inescapable stress, 231
Dose-response curves, 149 GABA, 477 Infection, 787
Drinking, 125, 183 GABA antagonist, 1 Influenza A PR8/34 virus, 167
Drug discrimination, 963 GABA receptors, 661 Ingestion, 473
Drug discrimination learning, 237, 593 GABA transaminase inhibitor, 1 Ingestive behavior, 679
Drug-induced side effects, 739 GABA,, 897 Inhibition, 219
Drug-naive and drug-experienced mice, 905 GABA, benzodiazepine receptor, 723 Inositol phosphates, 323
Drug-taking behavior, 561 GABA, receptor complex, 963 Instrumental behavior, 943
Dynorphin, 623 GABA, receptors, 77 Interaction, 73
Dynorphin A-(1-13), 587 GABAsg receptors, 77 Interleukin, 787
Dynorphin A(1-17), 331 Gastric fistula, 683 Interoceptive cues, 149
Dynorphin antibody, 331 Gastric transit, 411 Intracerebroventricular administration, 787
Dyskinesia, 427 Generalization, 593 Intranigral infusion, 427
Dystonia, 427 Genetics, 511 Intrathecal naloxone, 331
Glutamate, 423 Intraventricular, 21
8-OH-DPAT, 141, 487 Glybenclamide, 205 In vitro, 819
Elevated plus-maze test, 89 Glyburide, 205 In vivo electrochemistry (voltammetry),
Enantiomeric forms, 15 Grooming, 51, 673 715, 973
Endogenous dopamine, 819 Growth rate, 209 In vivo protection, 813
Endogenous opioids, 377, 483, 911 Guanine nucleotide binding or G-protein, In vivo receptor binding, 377
Endopeptidase 24.11, 777 689 Ion transport, 83
Endotoxin, 787 Ipsapirone, 569
Energy balance, 205, 617 Habituation, 117 Isoproterenol, 953
Energy expenditure, 617 Habituation in the open field, 799 IV, 265
Energy substrate utilization, 617 Haloperidol, 135, 195, 303, 323, 405, 739,
Enkephalinase, 777 759, 847, 853 Kainic acid, 397
Entrainment, 609 Heart rate, 259 x, 377
Ephedrine, 411 Hedonic, 745 x-Opiate receptors, 145
Eserine, 729 Heroin self-administration, 561 Ketanserin, 349
Estradiol, 637, 673 Hexobarbital, 73 Ketanserin binding, 631
Estrous cycle, 673 Hibernation, 9 Kindling, 275
Ethanol, 35, 283, 309, 477, 519, 535, 661, Hibernation trigger, 9
781 Hippocampus, 231, 689 Learned helplessness, 231, 423
Ethanol preference, 853, 857 Histamine, 95 Learning, 553, 733, 799
Ethological analysis, 67, 873 Histamine H, receptor, 95 Learning and memory, 959
Excitatory amino acid, 617 Homocysteic acid, 617 Learning behavior, 867
Exploratory behavior, 101 Horizontal movement, 269 Levodopa, 195
Extrapyrimidal movement disorders, 793 Hormone, 897 Lewis rat, 27
HOT and COLD Mice, 519 LHRH, 673
Feeding, 487, 917, 967 Hot plate, 145 LHRH antagonism, 673
Feeding and drinking, 787 Hotplate test, 361 Lingual epithelium, 83
Feeding behavior, 745 Housing conditions, 723 Lithium, 323
Fenfluramine, 653 HPLC, 303 Locomotion, 51
Fentanyl, 315 [’H]Raclopride, 377 Locomotor, 703
Fentanyl induced, 265 Human, 927 Locomotor activity, 95, 111, 135, 295, 341,
5-HT receptor subtypes, 349 Human butyrylcholinesterase (HuBChE), 391, 587, 637, 989
5-HT receptors, 125 889 Long-term effect, 867
5-HT,, agonists, 569 Human subjects, 781 Long-term potentiation, 847
5-HT,, antagonist(s), 67, 873 Hyperalgesia, 661 Lordosis, |
5-HT,, receptor(s), 141, 173, 289 Hyperlocomotion, 535 Lower lip retraction, 141
5-HT,- receptor, 289 Hypermotility, 881 L-Triiodothyronine, 729
SUBJECT INDEX
Macaca mulatta, 733 N-methyl-D-aspartate (NMDA), 959 Pregnanolone, 897
Macrophages, 605 Nociception, 205 Premenstrual syndrome, 897
Magnetic resonance imaging (MRI), 781 Noise, 35 Preoptic, 251
Magnetic resonance spectroscopy (MRS), Nongenomic, 1 Preoptic area, 39
781 Nonopioid, 117 Presynaptic, 51
Male F344 rat, 101 Nor-binaltorphimine, 331, 813 Pretreatment, 889
Marijuana, 967 Noradrenaline, 117, 411 Progesterone, 1, 897
Marmoset, 21 Norepinephrine, 101, 225, 231 Prolactin, 101
Mast cell-deficient (W/W”) mouse, 95 Norpseudoephedrine, 411 Prophylaxis, 889
Matching-to-sample, 435 Novelty-induced hypoalgesia, 117 Propranolol, 923
MDMA, 153, 439 Nucleus accumbens, 341, 477, 581, 703, Protection, 889
Meal pattern, 787 857, 881, 943 Protein kinase C, 553
Medial frontal cortex, 101 Pseudoephedrine, 411
Medial prefrontal cortex, 51, 857 Obese Zucker rats, 653 Psychomotor performance, 927
Melatonin, 45, 609 Obesity, 617 Psychomotor stimulant, 453
Memory, 799, 967 Olfactory bulbectomy, 77 Psychostimulant behavior, 715, 973
Mental performance, 463 Open-field behavior, 51 Puberty-accelerating pheromone, 835
Menthol, 259 Operant behavior, 581, 733 Puffing behavior, 527
Metabolism, 205, 617 Operant chambers, 315
Metergoline, 349 Operant punishment paradigm, 905 Quaternary metabolite, 739
Methamphetamine, 135, 989 Opiate(s), 237, 453, 917 Quinine, 315
Methionine-enkephalin, 841 Opiate antagonists, 593 Quinolinic acid, 303
Methionine-enkephalin fragments, 841 Opiate or opioid, 689
Methylscopolamine, 435 Opioid analgesia, 777 Race, 259
Mice, 15, 111, 605, 989 Opioid drugs, 315 (R)-a-Methylhistamine, 95
Microdialysis, 341, 477, 581 Opioid mediation, 373 Rapid eye movement sleep deprivation, 863
Midazolam, 331, 605 Opioid(s), 117, 183, 473, 745, 819, 917 Rapid smoking, 259
Midbrain raphe nuclei, 487 Oral movements, 427 Rat(s), 21, 45, 51, 73, 117, 131, 141, 161,
MK-801, 15, 881 Oral self-administration, 315 209, 243, 251, 309, 383, 415, 427, 473,
Modified forced swim test, 647 Organophosphate, 219 483, 569, 617, 751, 787. 819, 863, 889,
Molecular modeling, 295 Orofacial movements, 405 897, 959, 989
Monoamines, 365, 933 Ovariectomy, 673 Rat brain, 77
Mood, 927 Oxotremorine, 729 Rat fetus, 377
Morphine, 149, 205, 331, 341, 435, 473, Rate of decarbamylation, 827
483, 623, 745, 995 Pain, 361, 661 Reaction time, 463, 759, 769
Morris water maze, 889 Palatability, 745, 917 Reactivity, 415
Motivation, 581, 733, 943 Panic disorders, 89 Rearing, 269
Motor activity, 219 Paraventricular nucleus, 487, 933 Receptor, 575, 759, 967
Motor control, 793, 943 Paraventricular nucleus of the hypothala- Recombinant strains, 511
Mouse, 587, 799, 835 mus (PVN), 617 Rectal temperature, 295
MPTP, 739 Parkinsonism, 739 Reinforcement, 153, 183, 561
MR 1452, 145 Pattern discrimination, 535 Reinforcer, 927
mRNA, 575 Pentobarbital, 661 REM sleep, 215
p, 377 Pentylenetetrazol, 467 REM sleep deprivation, 111
p-Opiate, 519 Peptide YY, 679 Reserpine, 405
p-Opioid peptide agonists, 391 Perinatal undernutrition, 89 Respiratory arrest, 61
Muscarinic receptors, 219 Periodic mother deprivation, 609 Respiratory quotient, 617
Muscular rigidity, 265 Pertussin toxin, 689 Restricted feeding, 609
PGE,, 383 Reverse tolerance, 397
N-w-nitro-L-arginine methyl ester, 959 PGI,, 383 Review, 195
Naloxone, 117, 145, 473, 917, 995 Phagocytosis, 605 Reward, 183, 543, 917
Naltrexone, 145, 653 Phenelzine, 89 Reward or reinforcement, 689
NAN190, 141 Phenylpropanolamine, 411 Risperidone, 853
NBQX, 73 Phorbol ester binding, 553 Ritanserin, 349, 853, 857
Neostigmine, 435 Physostigmine, 435, 827 Ro 15-1788, 661, 683
Neostriatum, 943 Picrotoxin, 661 Rockland-Swiss mice, 923
Nervous system, 787 Pigeon, 435 Rodent, 967
Neural graft, 225 Pindolol, 141 Rotation-induced analgesia, 911
Neuroimmunology, 787 (—)-Pindolol, 873
Neuroimmunomodulation, 445 Pineal, 225 $20098, 45
Neuropeptide Y, 543 Pineal gland, 45 Saccharin, 483
Neuroreceptor, 251 Pinobind 5-HT,,, 67 Salbutamol, 653
Neurotoxicity, 739 PLO17, 391 (S)-a-Fluoromethylhistidine, 95
Nicotine, 131, 135, 209, 283, 303 Place conditioning, 543 Salt appetite, 473
Nigrostriatal and mesolimbic DAergic sys- Pleasure, 527 Salt taste, 83
tem, 709 Plus-maze, 467 Sardinian alcohol-preferring rats, 853
Nigrostriatum, 973 Postnatal, 219 SCH 23390, 759
Nitric oxide, 959 Postsynaptic, 51 Schedule-controlled behavior, 435
Nitrous oxide, 161 Potentiation, 237 SCN, 251
Nitrous oxide, 927 Prazosin, 61 Scopolamine, 215, 219, 435
NMDA antagonists, 15 Pre- and postweanling rats, 373 Screening models, 15
NMDA receptor, 423, 807 Precipitated abstinence, 683 SDZ 216-525, 873
VI SUBJECT INDEX
Sedation, 967 Stereotypy behavior, 269 Thyroparathyroidectomy, 243, 251
Seizures, 61, 365, 467 Steroid, 1 Thyroxine, 243, 251
Selected lines, 519 Straw suspension, 647 Time estimation, 733
Self-administration, 125, 689 Straw-climbing behavior, 647 Titration schedule, 435
Self-stimulation, 453 Stress, 35, 101, 167, 315, 445, 511, 605 Tolerance, 149, 283, 309, 341
Sensitization, 341 Stress-induced analgesia, 777 Tourette’s syndrome, 303
Septum, 251 Stress-induced antinociception, 373 Transduction, 83
Serotonin, 9, 21, 101, 125, 225, 289, 365, Striatum, 195, 303, 323, 341, 819, 863, Tremor, 729
477, 569, 715, 923, 973 867 Trophic factor, 195
Serotonin N-acetyltransferase rhythm, Structure-activity relationship, 295 Tryptophan hydroxylase, 9
609 Strychnine-insensitive glycine receptors,
Serotonin-2 receptors, 631 275 U 50-488, 145
7-Chlorokynurenic acid, 275 Subcellular distribution, 553 Unpredictable electric shock, 667
Sex and age differences, 985 Subjective effects, 927
Sex differences, 637, 777 Substantia nigra, 427 Vacuous jaw movements, 793
Sexual behavior, 1, 215 Supersensitivity, 397 Valproate, 323
Sexual conduct, 697 Suprachiasmatic, 251 Variable ratio, (VR), 667
Sexual differentiation, 637 Swimming activity, 111 Vasopressin, 309
Shock intensity, 569 Ventral tegmental area, 689, 857
Short-term memory, 733 Tail electric stimulation test, 373 Ventrolateral nucleus accumbens (vINAcc),
6-Hydroxydopamine, 397 Tail-flick, 149 715
SK&F38393, 269 Tail-tremor, 131 Ventromedial hypothalamus (VMH), 251
SK&F77434, 269 Tardive dyskinesia, 739 Vervet monkeys, 985
SK&F82958, 269 Target biting, 923 Vestibular compensation, 807
Skinner box, 667 Taste, 745 Virus infection, 167
Sleep disorders, 45 Temperature, 483, 953
Sleeping time, 73 Temporal discrimination learning, 27 Water consumption, 209
SM-3997, 647 Temporal response differentiation, 733 Water deprivation, 315
Smoking, 527 Terbutaline, 679 Water intake, 39
Social behavior, 67, 873 Testosterone, 637, 835 Weight cycling, 209
Social interaction, 161 Thermal balance, 953 Weight loss, 653
Soman, 889 Thermogenesis, 617 Withdrawal, 897
Spatial learning, 27, 415 Thermoregulatory behavior, 953
Spiperone, 759 Thigmotaxis, 269 Xylamidine, 349
Stearate microelectrode, 973 Thioctic acid, 799
Stereotyped behavior, 135 Thirst, 39 Yohimbine, 111
Stereotypic behavior, 51 3a,5a-Tetrahydroprogesterone, 897
Stereotypy, 637 Thyroid, 243, 251 Zymosan test, 605
PHARMACOLOGY BIOCHEMISTRY
& BEHAVIOR
VOLUME 46 1993
AUTHOR INDEX
Abbott, F. V., 661 Cahill, D. W., 303 Diaz-Véliz, G., 673 Grupp, L. A., 751
Ablordeppey, S. Y., 739 Callera, J. C., 39 Dobrosielski, M., 781 Grzybowska, J., 295
Abood, M. E., 575 Camargo, L. A. A., 39 Dohrn, C. S., 927 Guardiola-Lemaitre, B., 45
Agmo, A., 183 Campbell, D. B., 101 Dorow, J., 519 Gunne, L. M., 427
Aguilar-Garcia, A., 215 Campos, M. F., 21 Doyle, T. G., 745 Guzman-Flores, C., 985
Akarsu, E. S., 383 Canchola, E., 697 Drucker, G. E., 195 Gyarmati, S., 709
Albertson, T. E., 61 Carlisle, H. J., 953 Dube, S. N., 827
Allen, R. R., 733 Carpenter, C. L., 259 Dubuc, P. U., 953 Haefely, W., 553
Almeida, O. M. S., 729 Carvey, P. M., 195 Dussaubat, N., 673 Hagan, M. M., 679
Altenbaumer, M., 15 Caskey, N. H., 259 Hamdi, A., 863
Alvares, K., 315 Cepeda-Benito, A., 149 EI-Etri, M. M., 303 Hampe, S., 15
Amit, Z., 179 Chae, Y.-L., 231 Emerich, D. F., 303 Handa, R. J., 101
Andersen, S. L., 377 Chait, A., 361 Eng, F., 715 Hara, C., 667
Andrén, P. E., 427 Chakraborti, T. K., 219 Ervin, F. R., 985 Harding, S., 751
Anisman, H., 445, 511 Charalambous, A., 295 Estall, L. B., 959 Harsing, G. L., 709
Araki, Y., 131, 135 Chen, C.-J., 835 Hartmann, H., 799
Armstrong, S. M., 45 Chernet, E., 631 Falb, D. C., 483 Hasenfratz, M., 463, 527
Arts, K. S., 623 Chiu, T.-M., 781 Fan, F., 575 Hata, N., 101
Asakura, W., 111 Christie, M. J., 153 Farrar, J. D., 219 Heidbreder, C., 477
Ashani, Y., 889 Cicala, G. A., 959 Federman, I., 183 Hill, L. J., 125
Atrens, D. M., 153, 617 Ciccocioppo, R., 853, 857 Felder, C. C., 967 Hobson, H., 67, 873
Axelrod, J., 967 Cimetiere, C., 361 Feller, D. J., 519 Hodges, B. L., 161
Ayhan, I. H., 383 Clor, K. M., 995 Fernandez-Rial, J. C., 167 Holtzman, S. G., 813
Coalson, D. W., 927 Fields, J. Z., 195 Hong, E., 569
Babu, S. R., 827 Cohen, E., 889 Fiorella, D., 289 Hubbell, C. L., 473
Baeza, R., 673 Cohen, S. A., 799 Fischer, H. D., 867 Hudzik, T. J., 435
Balboa, J. L., 167, 605 Coleman, C., 35 Fitzgerald, A. L., 911 Hull, K. M., 411
Bardo, M. T., 819 Compton, D. R., 295 Flemming, D., 927 Huston-Lyons, D., 453
Baskin, P., 793 Cordoba, N. E., 89 Fletcher, P. J., 487
Battig, K., 463, 527 Corwin, R. L., 967 Forgie, M. L., 637 Innes, D. G. L., 777
Beauchemin, V., 77 Coscina, D. V., 487 Franklin, K. B. J., 661
Bell, R., 67, 873 Cousins, M. S., 581, 943 Freire-Garabal, M., 167, 605 Jackson, D. M., 153
Belmonte, A., 167, 605 Crain, S. M., 623 French, D., 989 Jacober, A., 527
Benavente, F., 673 Crawley, J. N., 967 Frye, C. A., 1 Janowsky, D., 365
Beninger, R. J., 543 Cross, M. K., 101 Fujimoto, J. M., 331, 623 Jarvik, M. E., 259
Bergstrasser, E., 867 Cullen, M. J., 415 Fukushima, T., 847 Jaskiw, G. E., 51
Berndt, C., 867 Cumin, R., 905 Furuno, K., 131, 135 Jenck, F., 905
Berridge, K. C., 745 Curtis, B. A., 161 Jibiki, I., 847
BBiilalnicnhgit,o n,M .,C . 14J.5, 917 Czech, D. A., 161 Gallo, M. A., 897 Johnson, A. E., 427
Bjork, A., 125 Gambarana, C., 423 Johnson, D. W., 341
Blokland, A., 27 Dal Pra, G., 463 George, M., 101 Johnson, R. G., 289
Blundell, J. E., 349 Dal Prd, P., 423 Gillam, M. P., 733 Jones, E. A., 125
Borkoski, J. P., 787 Dall, V., 73 Giraudo, S. Q., 917 Josselyn, S. A., 543
Borne, R. F., 739 Darlington, C. L., 807 Glennon, R. A., 459 Juarez, J., 985
Bowers, R. L., 483 Dawes, P., 117 Glick, S. D., 341
Boyd, N. E., 205 de Beaurepaire, R., 361 Gomita, Y., 131, 135 Kaddis, F. G., 703
Boyle, A. E., 179 De Cabo, C., 373 Gondoh, Y., 647 Kameyama, T., 587
Brandeis, R., 889 De Luca, L. A., Jr., 39 Gonzalez-Bahillo, J., 605 Kato, Y., 609
Braun, A. R., 51 De Montis, M. G., 423 Gordon, B. H., 101 Kavaliers, M., 777
Brock, J., 863 De Witte, P., 477 Gosnell, B. A., 745 Kehoe, P., 377
Broderick, P. A., 715, 973 Dean, J. E., 209 Grace, M. K., 917 Kirch, D. G., 323
Bryson, R., 35 DeBold, J. F., 1 Grady, D. R., 365 Kiyatkin, E. A., 561
Buffalo, E. A., 733 Del Vecchio, R. A., 265 Grant, S. J., 959 Klein, L. C., 315
Buhrfiend, C. M., 195 Dennis, T., 77 Grigdesby, C. F., 911 Klug, J. M., 397
Bunge, A., 463 Derlet, R. W., 61 Gross, J., 867 Knoll, J., 709
Burgess, L. H., 101 Deutsch, S. I., 963 Gross, T. M., 259 Kolachana, B. S., 51
Devane, W. A., 967 Grunberg, N. E., 315 Kolta, M. G., 819
Cabrera, T. M., 101 Diaz-Ruiz, O., 215 Grunwald, J., 889 Kornak, E. P., Jr., 715
Vill AUTHOR INDEX
Kornetsky, C., 453 Mora, S., 673 Roane, D. S., 205 Takashima, M., 609
Kramer, G., 231 Moreau, J.-L., 905 Robertson, J. M., 751 Takeuchi, Y., 609
Kubota, T., 847 Morimoto, K., 275 Robinson, J. K., 967 Tanaka, H., 667
Kulikov, A. V., 9 Moss, D. E., 679 Robinson, S. R., 377 Tanaka, M., 647
Kurokawa, K., 847 Miiller, W. E., 799 Robison, M., 35 Taukulis, H. K., 467
Myers, R. D., 125 Rochford, J., 117 Tekes, K., 709
Laino, C. H., 89 Rodriguez-Medina, M., 697 Teoh, S. K., 781
Lauchlan, C. L., 243 Najim, R. A., 995 Rosado, A., 697 Thielen, R. J., 723
Lavoie, N., 77 Namba, T., 275 Rosenblatt, M. R., 259 Tiffany, S. T., 149
Lawton, C. L., 349 Narayanan, S., 881 Ross, K., 863 Tilton, C. L., 575
Leibowitz, S. F., 933 Naruo, T., 667 Roux, J., 15 Timar, J., 709
Levine, A. S., 917 Navarro, V., 183 Rushing, P. A., 209 Toyoshi, T., 587
Li, R., 323 Nicastle, L. D., 483 Tseng, C.-C., 61
Li, T.-K., 173, 631, 723 Nishimura, H., 647 Saad, W. A., 39 Tsuda, A., 647
Lichtor, J. L., 927 Nordholm, L., 73 Sagen, J., 225
Liminga, U., 427 Norman, A. B., 303, 397 Sakai, N., 95 Uetrecht, R. L., 911
Lin, D., 195 Nozoe, S.-I., 667 Salamone, J., 793 Ukai, M., 587
Lin, H. Q., 153 Niujfiez, M. J., 167, 605 Salamone, J. D., 405, 581, 943 Umphress, S. M., 377
Lin, S., 295 Sanberg, P. R., 303 Uretsky, N. J., 703, 881
Lo, E. S., 195 O’Brien, R. A., 365 Sanger, G., 141 Urresta, F., 673
Lorens, S. A., 101 Ogawa, N., 667 Sansom, A. J., 807
Lukas, S. E., 781 Ohta, H., 111 Santos, R., 729 Vandenbergh, J. G., 835
Lumeng, L., 173, 631, 723 Oliveira, M. P., 21 Sardo, J., 35 Velazquez, G., 183
Lun, A., 867 Onodera, K., 95 Sarkar, M., 453 Velazquez-Moctezuma, J., 215
@rntoft, U., 73 Sauss, C., 575 Vergara-Onofre, M., 697
Maeyama, K., 95 Orsingher, O. A., 89 Scheller, D., 867 Vessotskie, J. M., 251
Maher, T. J., 411 Otsuki, S., 275 Schmidt, A., 73 Viveros, M. P., 373
Maickel, R. P., 911 Schoch, P., 553 Viadar, K., 51
Maillefer, R. H., 161 Padua, M., 183 Segal, R., 179 Voronova, I. P., 9
Makriyannis, A., 295 Paez, X., 933 Self, D. W., 689
Marciniak, G., 295 Palmour, R. M., 985 Semus, S. F., 295 Waddell, A. B., 813
Martin, B. R., 295, 575 Panconi, E., 15 Settles, A. M., 83 Wagner, G. C., 923
Martin, J. R., 553, 905 Panerai, A. E., 145 Sexton, R. H., 51 Wakita, S., 847
Martin, M. I., 373 Panocka, I., 853, 857 Shaham, Y., 315 Wala, E. P., 683
Martin, W. R., 683 Paronis, C. A., 813 Shanks, N., 511 Wallace, L. J., 703, 881
Massi, M., 853, 857 Paule, M. G., 733 Shaw, W.N., 653 Ward, K. M., 377
Mastropaolo, J., 963 Pelleymounter, M. A., 415 Shipley, M. T., 303 Watanabe, H., 111
Matray-Devoti, J., 923 Perrett, L., 141 Shults, J. M., 269 Watanabe, T., 95
Matsumoto, K., 111 Petty, F., 231 Sloan, J. W., 683 Wechsler, R., 715
Mayfield, R. D., 759, 769 Plata-Salaman, C. R., 787 Smith, B. R., 179 Weinberger, D. R., 51
McBride, W. J., 631, 723 Polidori, C., 857 Smith, P. F., 807 Welch, C. C., 917
McCarthy, W. J., 259 Pompei, P., 853 Smith, S. S., 897 Wenger, G. R., 435
McCullough, L. D., 581 Pope, C. N., 219 Smotherman, W. P., 377 Wetzel, P. J., 161
McCutcheon, N. B., 473 Popova, N. K., 9 Sokolowski, J. D., 943 Wilcox, R. E., 759, 769
McEachron, D. L., 243, 251 Porsolt, R. D., 15 Soliman, K. F. A., 283 Wilkins, D. R., II, 209
McGivern, R. F., 309 Pournaghash, S., 593 Somani, S. M., 827 Williams, H. L., 125
McGonigle, P., 251 Prasad, C., 863 Sortwell, C. E., 225 Williams, R. L., 283
McGregor, I. S., 153 Prickaerts, J., 27 Spear, L. P., 535 Willins, D. L., 881
McMillen, B. A., 125 Ptak, L. R., 195 Spear, N. E., 535 Wilson, L., 231
McNulty, O. M., 45 Pucilowski, O., 365 Spieler, K., 553 Winders, S. E., 209
Melcer, T., 309 Pujol, A., 373 Spirduso, W. W., 759, 769 Wing, L. L., 323
Melchior, C. L., 309 Sprague, J. E., 911 Witkin, J. M., 989
Meloni, D., 423 Quock, R. M., 161 Stein, E. A., 561 Wong, D. T., 173
Melton, P. M., 237 Stein, L., 689 Woods, B. T., 781
Menani, J. V., 39 Raaijmakers, W., 27 Steinpreis, R. E., 405 Wright, D. W., 435
Mendelson, J. H., 781 Rabin, R. A., 289 Stewart, J., 637 Wyatt, R. J., 323
Menéndez, J. A., 617 Rabold, J. A., 631 Stock, M. J., 953
Meneses, A., 569 Rady, J. J., 331 Stoll, S., 799 Yamada, N., 275
Mermelistein, P. G., 1 Rajachandran, L., 535 Stuart, J. F., 519 Yamaguchi, N., 847
Meyer, Melissa E., 391 Randall, P. K., 759, 769 Suaudeau, C., 361 Yamauchi, T., 609
Meyer, Merle E., 269, 391, 841 Raveh, L., 889 Suckow, M. A., 911 Yamazaki, S., 95
Midgley, D. E., 243 Redman, J. R., 45 Suemaru, K., 131, 135 Yanai, K., 95
Mierson, S., 83 Rees, G., 141 Sugishita, M., 609
Mizinga, K. M., 283 Reid, L. R., 173 Zacny, J. P., 927
Mollenauer, S., 35 Renzi, A., 39 Taddei, I., 423 Zalcman, S., 445
Molthen, R. C., 251 Rezvani, A. H., 365 Tagliamonte, A., 423 Zanol, M. D., 303
Moore, N. A., 141 Riley, A. L., 237, 593 Takahashi, K., 609 Zanzillari, R., 411